Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Niclosamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.97 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.97 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.97 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.97 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.97 |
| ▸ | GSK3B known ✓ | P49841 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.97 |
| ▸ | MAPT | P10636 | 3/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.97 |
| ▸ | NPC1 | O15118 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | HTT | P42858 | 2/20 | 0.97 |
| ▸ | RAB9A | P51151 | 2/20 | 0.97 |
| ▸ | AURKA | O14965 | 1/20 | 0.97 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.97 |
| ▸ | GMNN | O75496 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niclosamide SCHEMBL31098821 | 1.00 | KMT2A (0.97) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL29363878 | 0.99 | KMT2A (1.00) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL27365268 | 0.99 | KMT2A (1.00) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL28313524 | 0.99 | KMT2A (1.00) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL6662409 | 0.99 | KMT2A (1.00) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL67182 | 0.99 | KMT2A (1.00) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL27937315 | 0.97 | KMT2A (0.97) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL16686086 | 0.96 | KMT2A (0.95) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL1526777 | 0.96 | KMT2A (0.95) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL23753582 | 0.93 | LMNA (0.89) | KMT2AMEN1MAPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4125923-A1 | PHARMACEUTICAL COMPOSITIONS OF NICLOSAMIDE | Board of Regents, The University of Texas System (US) | 2023-02-08 | — | — | EP | claimed |
| CN-115515598-A | Pharmaceutical composition of niclosamide | 德克萨斯大学系统董事会 | 2022-12-23 | — | — | CN | claimed |
| WO-2021202928-A9 | PHARMACEUTICAL COMPOSITIONS OF NICLOSAMIDE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-01-13 | — | — | WO | claimed |
| WO-2021202928-A1 | PHARMACEUTICAL COMPOSITIONS OF NICLOSAMIDE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-10-07 | — | — | WO | claimed |
| WO-2021076922-A1 | PHARMACEUTICAL FORMULATIONS | FIRST WAVE BIO, INC. (US) | 2021-04-22 | — | — | WO | claimed |
| US-12076328-B2 | Pharmaceutical compositions of niclosamide | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-09-03 | — | — | US | disclosed |
| US-12036312-B2 | Non-aqueous topical compositions comprising a halogenated salicylanilide | UNION therapeutics A/S (DK) | 2024-07-16 | — | — | US | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-117597327-A | Pharmaceutical preparation | 第一波动生物制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-3338783-B1 | ANTIBACTERIAL USE OF HALOGENATED SALICYLANILIDES | UNION THERAPEUTICS AS (DK) | 2024-01-24 | — | — | EP | disclosed |
| US-20230414637-A1 | NICLOSAMIDE NASAL AND THROAT SPRAY | NEEDHAM MATERIAL SCIENCE LLC | 2023-12-28 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20110183889-A1 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-07-28 | — | — | US | disclosed |
| CN-101842101-A | Salicylanilide modified peptides for use as oral therapeutics | UNIV CALIFORNINA | 2010-09-22 | — | — | CN | disclosed |
| EP-2182956-A2 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | The Regents of the University of California (US) | 2010-05-12 | — | — | EP | disclosed |
| CN-101522207-A | Salicylanilides enhance oral delivery of therapeutic peptides | UNIV CALIFORNINA (US) | 2009-09-02 | — | — | CN | disclosed |
| US-20090163408-A1 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-25 | — | — | US | disclosed |
| EP-2049137-A2 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | The Regents of the University of California (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009032749-A2 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNINA (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2008021088-A2 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNINA (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | MEN1 3463/4885JAK2 1988/4885EGFR 4732/4885 |
| US-20090163408-A1 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | DNPEP, NGLY1, VIP | MEN1 3158/4885JAK2 1792/4885EGFR 1388/4885 |
| US-20110183889-A1 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | DNPEP, PTMS, NGLY1 | MEN1 1625/4885JAK2 1447/4885EGFR 952/4885 |
| US-12036312-B2 | Non-aqueous topical compositions comprising a halogenated salicylanilide | CUTA, PTPN21, ABL2 | MEN1 4675/4885JAK2 317/4885EGFR 176/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | MEN1 3470/4885JAK2 1892/4885EGFR 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.